Sean Savitz, MD
Vascular Neurology · Houston, TXNPI 1174639173
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $15,463 of the $20,245 with a category attached, or 76.4%. AbbVie accounts for 76.7% of it on its own, with 4 other manufacturers making up the rest. Reporting peaked in 2021 at $6,463 and has fallen 62.5% since, to $2,426 in 2025.
Across 17 payments — averaging $1190.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$16K
- Medtronic$3K
- F. Hoffmann-la Roche AG$2K
- Genentech, Inc.$40
- Teva Pharmaceuticals USA, Inc.$26
Across 23 payments — averaging $7369.62 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sunovion Pharmaceuticals Inc.$59K
- Genentech, Inc.$56K
- AbbVie$30K
- Ipsen Pharma SAS$22K
- F. Hoffmann-la Roche AG$3K
What the payments were for
- Consulting fees$15,46376%
- Speaking & faculty fees$4,66123%
- Food & beverage$820%
- Education$400%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 13 | $15,518 |
| Medtronic | 1 | $2,990 |
| F. Hoffmann-la Roche AG | 1 | $1,671 |
| Genentech, Inc. | 1 | $40 |
| Teva Pharmaceuticals USA, Inc. | 1 | $26 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$20,245 in reported general payments places this provider in the 85th percentile of 76 vascular neurology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other vascular neurology in Houston
- John VolpiHouston$407K
- Amrou SarrajHouston$182K
- Sunil ShethHouston$54K
- Haris KamalHouston$21K
- Louise McCulloughHouston$14K
- Michael NahhasHouston$10K
- Rajan GadhiaHouston$5K
- Mohammad El-GhanemHouston$5K
- Robert RegenhardtHouston$5K
- Joseph FriesHouston$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.